Evidence of PSA screening efficacy lacking

March 04, 2002

There is no evidence to support speculation that prostate-specific antigen (PSA) screening has contributed to a decline in prostate cancer mortality rates since 1995, a new study has determined. The value of such screening remains controversial. Some American authorities have called for cancer screening in men who ask about the PSA test, while the Canadian Urological Association and most health authorities in Europe still discourage it. The number of men becoming candidates for such screening is growing rapidly because of the aging of the baby-boom generation. Dr. François Meyer and colleagues divided the adult males of Quebec who were 50 years or older into 15 birth cohorts and computed the change in prostate cancer incidence between 1989 and 1993, and the change in prostate cancer mortality between 1995 and 1999. They then assessed the correlation between the changes in cancer incidence and the subsequent changes in prostate cancer mortality. The authors also split the population into 15 regional populations and repeated the analysis, which yielded a similar outcome, leading them to conclude that PSA screening cannot explain the decline in prostate cancer mortality in the population studied. The authors warn that the results need to be considered with caution because PSA screening may well be shown to be an effective tool in preventing or postponing death from prostate cancer, but the evidence does not yet exist to support such a claim.

In a related commentary, André Vis says answers on whether PSA screening is truly beneficial at a population level will only be provided when large-scale randomized controlled trials -- several of which were begun in the US and Europe in the early 1990s -- are completed.
-end-
p. 586 PSA screening and prostate cancer mortality
-- F. Meyer et al

p. 600 Does PSA screening reduce prostate cancer mortality?
-- A.N. Vis

Canadian Medical Association Journal

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.